Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 9,945 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single-arm Clear all

Conditions: HIV Prevention
Interventions: Q-Griffithsin (Q-GRFT) enema, Placebo enema; Drug · Other
Lead sponsor: Rhonda Brand; Other
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer
Interventions: Hyperpolarized 13C-Pyruvate; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Traumatic Brain Injury, Chronic Traumatic Encephalopathy, Mild Cognitive Impairment
Interventions: Amyvid PET Scan, T807 PET scan; Drug
Lead sponsor: Samuel Gandy; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL), Marginal Zone B Cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High Grade Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma (MCL)
Interventions: ME-401, Rituximab, Zanubrutinib; Drug
Lead sponsor: MEI Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 23
States / cities: Tucson, Arizona • Corona, California • Miami, Florida + 18 more

Conditions: HIV Infections
Interventions: VH4527079; Biological
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Malignant Pleural Mesothelioma (MPM)
Interventions: cyclophosphamide, CAR T cells; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
Interventions: Sonrotoclax; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Birmingham, Alabama • Fort Wayne, Indiana • New Orleans, Louisiana + 3 more

Conditions: Lipoma
Interventions: STARMed VIVA Combo RF System; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
Interventions: Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization; Drug · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Constipation
Interventions: ISOThrive Prebiotic Nectar; Dietary Supplement
Lead sponsor: ISOThrive Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Manassas, Virginia

Conditions: Total Knee Replacement
Interventions: Bone wax; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Syosset, New York

Conditions: Acute Ischemic Stroke, Large Vessel Occlusion
Interventions: Mechanical Thrombectomy (Penumbra System with Thunderbolt); Device
Lead sponsor: Penumbra Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 32
States / cities: Goodyear, Arizona • San Diego, California • Englewood, Colorado + 29 more

Conditions: Lymphoma. Non-Hodgkin
Interventions: Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 6 more

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions: Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA), Neoadjuvant Chemotherapy (NAC); Device · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Parkinson's Disease
Interventions: Deep Brain Stimulation, DBS surgery; Device · Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Interventions: NVX-CoV2705 Vaccine; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Phoenix, Arizona • Austin, Texas

Conditions: Portal Hypertension, TIPS
Interventions: BD Liverty™ TIPS Stent Graft; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 17
States / cities: Palo Alto, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 12 more

Conditions: Compensated Chronic Hepatitis B
Interventions: Telbivudine/LDT600A; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 16 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 5
States / cities: Chicago, Illinois • Boston, Massachusetts • Bayside, New York + 1 more

Conditions: Prostate Adenocarcinoma, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7
Interventions: Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Vismodegib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Ann Arbor, Michigan • Detroit, Michigan • Durham, North Carolina + 2 more

Conditions: Critical Illness
Interventions: Muscle Ultrasound, Nerve Conduction Study, Electromyography; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hyperphosphatemia, Chronic Kidney Disease
Interventions: Placebo, Sevelamer carbonate; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Up to 18 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more

Conditions: Nonsuicidal Self Injury, Suicidal Ideation, Depression, Anxiety
Interventions: Self-guided digital intervention for NSSI, Digital intervention for NSSI with coaching, Active control; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 24 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions: Etirinotecan pegol (NKTR-102); Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Coronary Artery Disease, Chest Pain, Coronary Atherosclerosis, Stress Testing
Interventions: Cardiac CT Angiography, Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram); Procedure
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Griffithsin-based Rectal Microbicide for PREvention of Viral ENTry (PREVENT)

Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

RFA for Superficial Lipomas

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Open Label Tolerability Study of ISOThrive Prebiotic Nectar (MIMO) in Subjects With Constipation

Bone Wax Use for Hemostasis During Primary Unilateral Total Knee Arthroplasty

THUNDER: Acute Ischemic Stroke Study With the Penumbra System® Including Thunderbolt™ Aspiration Tubing

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

EUS-RFA PANCARDINAL-1 Trial

Clinical Outcomes of Deep Brain Stimulator (DBS) Electrodes Placed Using Intraoperative Computed Tomography (CT) and Frameless Stereotaxis

A Strain Change Study for SARS-CoV-2 rS Vaccines

The BD Liverty™ TIPS Stent Graft Study

Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks

Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer

The Diagnosis and Incidence of Critical Illness Polyneuromyopathy in Medical and Neurosurgical ICU Patients

An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

Digital Mental Health Intervention for Nonsuicidal Self-Injury in Young Adults

Etirinotecan Pegol (NKTR-102) in NSCLC

CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification